Pyroxamide

Pyroxamide is a potent inhibitor of histone deacetylase 1 (HDAC1) with an ID50 of 100 nM. Pyroxamide can induce apoptosis and cell cycle arrest in leukemia.

Product information

CAS Number: 382180-17-8

Molecular Weight: 265.31

Formula: C13H19N3O3

Chemical Name: N-hydroxy-N'-(pyridin-3-yl)octanediamide

Smiles: ONC(=O)CCCCCCC(=O)NC1C=NC=CC=1

InChiKey: PTJGLFIIZFVFJV-UHFFFAOYSA-N

InChi: InChI=1S/C13H19N3O3/c17-12(15-11-6-5-9-14-10-11)7-3-1-2-4-8-13(18)16-19/h5-6,9-10,19H,1-4,7-8H2,(H,15,17)(H,16,18)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 125 mg/mL (471.15 mM; Need ultrasonic)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Pyroxamide (1.25-20.0 μM; 24-72 hours) suppresses RD and RH30B cells growth, pyroxamide resulted in 44% dead cells for 72 h at 20.0 μM, results in 86% dead cells in culture. Pyroxamide (10.0-20.0 μM; 48 hours) shows sub-G1 fractions of 45.0% and 72.3% at 10.0 and 20.0 μM, respectively.

References:

1. Butler LM, et al. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res. 2001 Apr;7(4):962-70.
2. Kutko MC, et al. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro.Clin Cancer Res. 2003 Nov 15;9(15):5749-55.

Products are for research use only. Not for human use.